InfuSystem Holdings, Inc. (NYSE:INFU) Receives $14.50 Average Target Price from Brokerages

Shares of InfuSystem Holdings, Inc. (NYSE:INFU) have earned an average recommendation of “Buy” from the five ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, two have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $14.50.

Several equities research analysts have issued reports on the stock. Roth Capital reaffirmed a “buy” rating and set a $14.00 price target (up from $13.00) on shares of InfuSystem in a research note on Tuesday, November 4th. Zacks Research downgraded shares of InfuSystem from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Finally, Lake Street Capital started coverage on shares of InfuSystem in a research note on Monday, September 22nd. They issued a “buy” rating and a $15.00 target price for the company.

InfuSystem Stock Up 4.1%

Shares of NYSE:INFU opened at $9.34 on Thursday. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $189.94 million, a P/E ratio of 155.69 and a beta of 1.71. InfuSystem has a 52-week low of $4.61 and a 52-week high of $11.04. The stock’s fifty day simple moving average is $9.80 and its 200-day simple moving average is $8.27.

Hedge Funds Weigh In On InfuSystem

Several institutional investors have recently added to or reduced their stakes in the business. Kestra Private Wealth Services LLC acquired a new stake in InfuSystem in the 3rd quarter worth about $287,000. Qube Research & Technologies Ltd lifted its holdings in shares of InfuSystem by 84.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 69,353 shares of the company’s stock worth $718,000 after acquiring an additional 31,854 shares during the period. Millennium Management LLC boosted its position in shares of InfuSystem by 14.3% in the third quarter. Millennium Management LLC now owns 415,178 shares of the company’s stock worth $4,301,000 after acquiring an additional 51,925 shares during the last quarter. Centiva Capital LP purchased a new stake in InfuSystem in the third quarter valued at approximately $521,000. Finally, Bank of America Corp DE increased its position in InfuSystem by 65.5% during the third quarter. Bank of America Corp DE now owns 29,786 shares of the company’s stock worth $309,000 after purchasing an additional 11,792 shares during the last quarter. 71.13% of the stock is currently owned by institutional investors and hedge funds.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.